Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSX: NUMI )

0.0800 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,060
Open 0.0800
Bid (Size) 0.0750 (1,160)
Ask (Size) 0.0800 (590)
Prev. Close 0.0800
Today's Range 0.0750 - 0.0800
52wk Range 0.0650 - 0.2750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced  
Via Benzinga
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-33.33%
-33.33%
1 Month
-15.79%
-15.79%
3 Month
-42.86%
-42.86%
6 Month
-36.00%
-36.00%
1 Year
-54.29%
-54.29%

More News

Read More
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
From Virtual Investor Conferences
Via GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Justera Health, Nextech3D.ai, Numinus Wellness, Sona Nanotech and Fineqia International Discussing Their Latest News
Via ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
Via ACCESSWIRE
Healing CREI Announces a Partnership with Numinus Wellness Inc.
Via Newsfile
Numinus Expands Research Capabilities with new Phoenix Clinical Research Site
Via PressReach
Numinus Wellness Inc. Reports Q1 2023 Results
Via PressReach
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
From Virtual Investor Conferences
Via GlobeNewswire
Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
Via PressReach
Alberta Becomes the First Province to Regulate Psychoactives for Therapeutic Purposes
Via PressReach
Topics Law Enforcement
Exposures Legal
Numinus Wellness Inc. Reports Q4 2022 and Annual Results
Via PressReach
Colorado Has Just Legalized The Use of Magic Mushrooms
Via PressReach
Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
Via PressReach
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Colorado to Vote on Legalizing Psychoactives in November
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
Via PressReach
Topics Cannabis
Exposures Cannabis
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
Via FinancialNewsMedia
Mental Health Claims up 75% Since 2019
Via PressReach
Mental Health Claims up 75% Since 2019
Via FinancialNewsMedia
Numinus Opens New Clinic in Montreal to Increase Access to Ketamine Therapy for Mental Health
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.